New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
11:56 EDTQGENQIAGEN moves up after strong earnings and guidance, levels to watch
The shares are up over 6.5% after the company turned in an earnings beat and raised guidance. At the current price of $21.28, next resistance is at $21.90. A big area of resistance stretching back several year is at $23.83. That will be an important test if and when shares get closer to that objective. Looking back on a ten year monthly chart will make that evident. Support is currently at $20.27.
News For QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 16, 2015
16:07 EDTQGENTokai Pharmaceuticals expands collaboration with QIAGEN
Subscribe for More Information
16:06 EDTQGENQIAGEN acquires circulating tumor cell technology from AdnaGen
QIAGEN (QGEN) announced an expansion of itsportfolio of liquid biopsies through the acquisition of an technology that enables enrichment and molecular analysis of circulating tumor cells from blood samples. The proprietary technology from AdnaGen allows a complete solution for the detection and analysis of CTCs for clinical applications. QIAGEN also announced a new partnership with Tokai Pharmaceuticals (TKAI) to combine this new CTC technology with a molecular assay to co-develop and commercialize a companion diagnostic for Tokai's novel drug compound galeterone, which is in late-stage clinical trials for treatment of castration-resistant prostate cancer. The non-invasive test will determine the expression of the AR-V7 biomarker, which in recent studies has demonstrated potential utility to guide therapy choice in CRPC patients. Financial terms for the AdnaGen acquisition and the Tokai partnership were not disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use